Gilead ordered to pay $200m for infringing Merck hepatitis C patents
Jury awards figure that is 10% of the $2 billion Merck was seeking for Gilead infringing hepatitis C treatment patents
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: